Related Experiment Video
Updated: Aug 6, 2026
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Inhibition of platelet aggregation by moxalactam and free N-methylthiotetrazole
C S Ingalls1, P Somani, E H Freimer
1Department of Microbiology, Medical College of Ohio, Toledo.
Abstract:
The effects of moxalactam and free N-methylthiotetrazole (N-MTT) in vitro on platelet aggregation induced by adenosine diphosphate (ADP), arachidonic acid, collagen, epinephrine, or ristocetin were determined. Moxalactam at concentrations of 1.9 mM and 5.7 mM inhibited platelet aggregation induced by ADP, arachidonic acid, epinephrine, and ristocetin. Although the aggregatory activity of collagen was not inhibited with 1.9 mM moxalactam, an increase in the concentration of moxalactam to 5.7 mM significantly inhibited collagen-induced platelet aggregation. Inhibition of platelet aggregation by free N-MTT was also concentration dependent. The lowest concentration of N-MTT used in this study, 5.7 mM, inhibited platelet aggregation induced by both arachidonic acid and ristocetin. At a concentration of 28 mM, N-MTT inhibited aggregation induced by ADP, collagen, epinephrine, and ristocetin, but not by arachidonic acid. At 57 mM N-MTT, almost complete inhibition of platelet aggregation occurred for all five agonists tested.
Insights
Moxalactam and N-methylthiotetrazole (N-MTT) inhibit platelet aggregation in a dose-dependent manner. These findings are crucial for understanding potential bleeding risks associated with moxalactam use.
Area of Science:
- Pharmacology
- Hematology
- Biochemistry
Background:
- Moxalactam is a beta-lactam antibiotic with potential side effects.
- N-methylthiotetrazole (N-MTT) is a side chain found in some cephalosporins, including moxalactam.
- Platelet aggregation is a critical process in hemostasis.
Purpose of the Study:
- To investigate the in vitro effects of moxalactam and free N-methylthiotetrazole (N-MTT) on platelet aggregation.
- To determine the concentration-dependent inhibitory effects of these compounds on platelet aggregation induced by various agonists.
Main Methods:
- In vitro assessment of platelet aggregation.
- Utilized agonists: adenosine diphosphate (ADP), arachidonic acid, collagen, epinephrine, and ristocetin.
- Tested varying concentrations of moxalactam and N-MTT.
Main Results:
- Moxalactam inhibited platelet aggregation induced by ADP, arachidonic acid, epinephrine, and ristocetin at 1.9 mM and 5.7 mM.
- Moxalactam (5.7 mM) significantly inhibited collagen-induced aggregation.
- Free N-MTT demonstrated concentration-dependent inhibition of platelet aggregation, affecting all tested agonists at higher concentrations (57 mM).
Conclusions:
- Both moxalactam and free N-MTT possess antiplatelet activity.
- The observed inhibition of platelet aggregation suggests a potential mechanism for increased bleeding risk with moxalactam therapy.
- Further investigation into the clinical implications of these in vitro findings is warranted.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
01:10Drugs that Destabilize Microtubules
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...